Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.verified

TRVI

Price:

$3.97

Market Cap:

$354.78M

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.[Read more]

Industry

Biotechnology

IPO Date

2019-05-07

Stock Exchange

NASDAQ

Ticker

TRVI

The Enterprise Value as of December 2024 (TTM) for Trevi Therapeutics, Inc. (TRVI) is 339.84M

According to Trevi Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 339.84M. This represents a change of 32.38% compared to the average of 256.72M of the last 4 quarters.

Trevi Therapeutics, Inc. (TRVI) Historical Enterprise Value (quarterly & annually)

How has TRVI Enterprise Value performed in the past?

The mean historical Enterprise Value of Trevi Therapeutics, Inc. over the last ten years is 58.53M. The current 339.84M Enterprise Value has changed 57.96% with respect to the historical average. Over the past ten years (40 quarters), TRVI's Enterprise Value was at its highest in in the September 2024 quarter at 322.54M. The Enterprise Value was at its lowest in in the December 2017 quarter at -13318630.00.

Quarterly (TTM)
Annual

Average

58.53M

Median

54.33M

Minimum

-12947821.25

Maximum

141.16M

Trevi Therapeutics, Inc. (TRVI) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Trevi Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.23%

Maximum Annual Enterprise Value = 141.16M

Minimum Annual Increase = -2895.20%

Minimum Annual Enterprise Value = -12947821.25

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023101.65M-16.10%
2022121.15M-2895.20%
2021-4334393.56-133.57%
202012.91M-199.73%
2019-12947821.25-123.68%
201854.67M1.23%
201754.00M-61.74%

Trevi Therapeutics, Inc. (TRVI) Average Enterprise Value

How has TRVI Enterprise Value performed in the past?

The current Enterprise Value of Trevi Therapeutics, Inc. (TRVI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

72.82M

5-year avg

43.69M

10-year avg

58.53M

Trevi Therapeutics, Inc. (TRVI) Enterprise Value vs. Peers

How is TRVI’s Enterprise Value compared to its peers?

Trevi Therapeutics, Inc.’s Enterprise Value is greater than aTyr Pharma, Inc. (138.44M), greater than Cue Biopharma, Inc. (41.71M), greater than AN2 Therapeutics, Inc. (6.98M), greater than BioAtla, Inc. (-24961978.00), greater than Spero Therapeutics, Inc. (-20557187.00), greater than Bolt Biotherapeutics, Inc. (28.60M), greater than Coherus BioSciences, Inc. (303.85M), less than Gracell Biotechnologies Inc. (5.66B), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Foghorn Therapeutics Inc. (261.58M), greater than C4 Therapeutics, Inc. (278.51M), greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than Prelude Therapeutics Incorporated (69.78M), greater than Rezolute, Inc. (244.24M), greater than Lyra Therapeutics, Inc. (22.74M), greater than SQZ Biotechnologies Company (12.09M), greater than Protara Therapeutics, Inc. (129.55M), greater than TRACON Pharmaceuticals, Inc. (-6160275.00), greater than Seer, Inc. (122.73M), less than ORIC Pharmaceuticals, Inc. (533.31M), greater than Anebulo Pharmaceuticals, Inc. (38.14M), less than Cullinan Oncology, Inc. (615.40M),

Build a custom stock screener for Trevi Therapeutics, Inc. (TRVI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Trevi Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Trevi Therapeutics, Inc. (TRVI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Trevi Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Trevi Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Trevi Therapeutics, Inc. (TRVI)?

What is the 3-year average Enterprise Value for Trevi Therapeutics, Inc. (TRVI)?

What is the 5-year average Enterprise Value for Trevi Therapeutics, Inc. (TRVI)?

How does the current Enterprise Value for Trevi Therapeutics, Inc. (TRVI) compare to its historical average?